2025年1月13日 · 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Dr. Hank Mansbach is chief medical officer of 89bio. Dr. Mansbach has more than 20 years of clinical, regulatory, and medical affairs experience working across all stages of product development in a wide range of disease states.

2023年6月24日 · 19. 89bio. Pegozafermin phase 2b (ENLIVEN) topline results in nonalcoholic steatohepatitis (NASH). Corporate Presentation. Published online March 2023. 20. Loomba R. Pegozfermin led to improved liver histology, liver-related non-invasive tests and metabolic profile, with favorable safety and tolerability, in an open-label cohort of a Phase 1b ...

MASH is a severe and progressive liver disease accompanied by multiple metabolic abnormalities. MASH is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) defined by liver inflammation and injury.

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 —Alignment reached on key elements of the NASH development strategy, including accelerated approval pathway for both F4 and F2-F3 NASH patients using histology—

"We are excited to initiate our first Phase 3 trial in MASH for pegozafermin, a leading and potentially best-in-class FGF21 analog, which strikes the right balance of sustained efficacy, favorable tolerability, and dosing convenience,” said Hank Mansbach, Chief Medical Officer of …

Visit the study page on clinicaltrials.gov | Contact enliven@89bio.com – Pegozafermin for Severe Hypertriglyceridemia (SHTG) STUDY TITLE

“At 89bio, we know attracting and supporting great people is essential to achieving our mission of transforming patients’ lives. This focus on our employees has led to a vibrant and dynamic corporate culture where everyone is seen as a critical part of our success.”

"We are excited to present additional analyses from our Phase 2b ENLIVEN trial at this year’s Liver Meeting, which reinforce pegozafermin's potential effectiveness in reversing fibrosis and preventing progression to cirrhosis in patients with advanced MASH," said Hank Mansbach, Chief Medical Officer of 89bio.

SAN FRANCISCO, Nov. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced additional data from a post-hoc analysis of the ENLIVEN Phase 2b trial ...